$1.36
-0.05 (-3.55%)
Open$1.37
Previous Close$1.41
Day High$1.43
Day Low$1.35
52W High$2.57
52W Low$1.12
Volume—
Avg Volume407.8K
Market Cap48.24M
P/E Ratio—
EPS$-0.82
SectorBiotechnology
Analyst Ratings
Strong Buy
10 analysts
Price Target
+2,294.9% upside
Current
$1.36
$1.36
Target
$32.57
$32.57
$26.16
$32.57 avg
$50.99
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 10.28M | 9.86M | 9.80M |
| Net Income | -1,154,434 | -865,846 | -1,110,362 |
| Profit Margin | -11.2% | -8.8% | -11.3% |
| EBITDA | -1,433,621 | -1,413,990 | -1,277,421 |
| Free Cash Flow | -904,387 | -870,700 | -861,997 |
| Rev Growth | +11.1% | +6.2% | +2.7% |
| Debt/Equity | 0.32 | 0.28 | 0.29 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $214.98 | -1.15% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $353.28 | +0.41% | 24.7 | 190.40B |
| GILD | Gilead Sciences Inc | $140.30 | +0.67% | 19.6 | 166.66B |
| VRTX | Vertex Pharmaceuticals Inc | $447.26 | +0.16% | 29.1 | 114.87B |
| REGN | Regeneron Pharmaceuticals | $777.25 | +0.60% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.73 | -0.65% | 139.7 | 43.84B |